Federated Hermes Inc. decreased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,009 shares of the company’s stock after selling 1,533 shares during the quarter. […]
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have received an average recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. […]
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03, Briefing.com reports. The business had revenue of $196.60 million for the quarter, compared to analysts’ expectations of $194.80 million. Myriad Genetics had […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of […]